Open Access

Understanding the clinical spectrum of complicated Plasmodium vivax malaria: a systematic review on the contributions of the Brazilian literature

  • Marcus VG Lacerda1, 2, 3Email author,
  • Maria PG Mourão1, 2, 3,
  • Márcia AA Alexandre1, 2, 3,
  • André M Siqueira1, 2,
  • Belisa ML Magalhães1, 2,
  • Flor E Martinez-Espinosa1, 2, 4,
  • Franklin S Santana Filho1, 2,
  • Patrícia Brasil5,
  • Ana MRS Ventura6,
  • Mauro S Tada7,
  • Vanja SCD Couto8,
  • Antônio R Silva9,
  • Rita SU Silva10 and
  • Maria GC Alecrim1, 2, 3
Malaria Journal201211:12

DOI: 10.1186/1475-2875-11-12

Received: 20 October 2011

Accepted: 9 January 2012

Published: 9 January 2012

Abstract

The resurgence of the malaria eradication agenda and the increasing number of severe manifestation reports has contributed to a renewed interested in the Plasmodium vivax infection. It is the most geographically widespread parasite causing human malaria, with around 2.85 billion people living under risk of infection. The Brazilian Amazon region reports more than 50% of the malaria cases in Latin America and since 1990 there is a marked predominance of this species, responsible for 85% of cases in 2009. However, only a few complicated cases of P. vivax have been reported from this region. A systematic review of the Brazilian indexed and non-indexed literature on complicated cases of vivax malaria was performed including published articles, masters' dissertations, doctoral theses and national congresses' abstracts. The following information was retrieved: patient characteristics (demographic, presence of co-morbidities and, whenever possible, associated genetic disorders); description of each major clinical manifestation. As a result, 27 articles, 28 abstracts from scientific events' annals and 13 theses/dissertations were found, only after 1987. Most of the reported information was described in small case series and case reports of patients from all the Amazonian states, and also in travellers from Brazilian non-endemic areas. The more relevant clinical complications were anaemia, thrombocytopaenia, jaundice and acute respiratory distress syndrome, present in all age groups, in addition to other more rare clinical pictures. Complications in pregnant women were also reported. Acute and chronic co-morbidities were frequent, however death was occasional. Clinical atypical cases of malaria are more frequent than published in the indexed literature, probably due to a publication bias. In the Brazilian Amazon (considered to be a low to moderate intensity area of transmission), clinical data are in accordance with the recent findings of severity described in diverse P. vivax endemic areas (especially anaemia in Southeast Asia), however in this region both children and adults are affected. Finally, gaps of knowledge and areas for future research are opportunely pointed out.

Keywords

Malaria Plasmodium vivax Brazil Severity Clinical aspects Anaemia Systematic review

Background

Plasmodium vivax is the most geographically widespread species of Plasmodium causing human disease, with most cases reported in Central and Southeast Asia, in the horn of Africa and in Latin America [1]. It is considered to be a potential cause of morbidity and mortality amongst the 2.85 billion people living at risk of infection, excluding the large African populations who are mostly Duffy negative and, therefore, naturally less susceptible to this infection. However recent data suggest that the parasite is evolving and may use alternative receptors other than Duffy (DARC) for erythrocyte invasion [2]. It is estimated that 5.5% of the population under risk live in the Americas [3]. The major biological characteristic of this parasite is the presence of liver hypnozoites responsible for the frequent relapses, which add a substantial number of cases to the general burden of the disease, what is being faced as one of the most challenging bottlenecks for vivax malaria eradication [4].

Although often regarded as causing a benign infection, there is recent increasing evidence that the overall burden, economic impact, and severity of P. vivax have been underestimated, in part due to a bias in the scientific literature which traditionally devoted most of its attention to the more lethal parasite Plasmodium falciparum, probably as a reflection of a more substantial funding [5]. Until 16 October 2011, the search in MEDLINE using P. vivax as keyword retrieved 5,026 indexed abstracts; using P. falciparum, on the other hand, retrieved almost five times more abstracts: 25,807. Even in places where P. vivax represents the major local problem to be tackled, clinical research is still focused on P. falciparum[6]. There is robust evidence in the past decade from hospital-based studies in India and Indonesia that P. vivax is able to cause severe disease [7, 8]. Some authors argue that this clinical severity may only now be properly recognized and announced by researchers in the field, but these complications apparently are not new from a historical perspective [9]. Actually, the case fatality rate (CFR) related to malarial infections in the English marshes during the 16th and 17th centuries, corresponding to the Little Ice Age, suggest that P. vivax (a parasite more prone to persist in vectors even under low temperatures) may have killed part of this population already victimized by famine [10]. During the first half of the 20th century, malariotherapy in patients with neurosyphilis, using essentially the 'non-severe' P. vivax parasite, led to diverse complications, CFR ranging from 3.3 to 30.3% [11]. The major related complications in these co-infected patients were liver damage, ruptured spleen, jaundice, delirium, uncontrolled vomiting and persistent headaches [11]. That reinforces the concept that P. vivax infection may synergize with other co-morbidities resulting in more complicated disease. Added to local geographical and social determinants, wide Annual Parasite Incidence (API) and CFR variations due to this species are seen around the world.

In summary, P. vivax, which has long been neglected and mistakenly considered 'benign' [12], is receiving an increasing amount of importance in the debates taking place on malaria epidemiology and control, drug resistance, pathogenesis and vaccines [13]. As reviewed elsewhere, the good clinical characterization of severe disease in vivax infection is the first step to understand how the inflammatory response to this parasite contributes to pathogenesis [14].

Traditionally, Brazil has been responsible for almost half of all cases of malaria in Latin America. In 2009, 308,498 cases of malaria were reported in this country (257,571 caused by P. vivax), representing 54.9% of all the malaria reported in the Americas [15]. Cases are virtually restricted to the Amazon Basin (constituted by the states of Amazonas, Acre, Roraima, Amapá, Pará, Tocantins, Rondônia, and parts of Mato Grosso and Maranhão). Amazonian urban agglomerations under continuous economical development trigger intense migration flows, such as in the city of Manaus (in the Western Brazilian Amazon), helping to maintain the disease under endemic levels [16, 17]. Malaria in Brazil is mostly related to P. vivax since the 1990s, when the available tools for control at the moment were put together and intensified, such as the fast diagnosis through thick blood smear (TBS) in all febrile patients, and free access to anti-malarials, integrated through a decentralized primary care-centred public health system [18]. Allied to that, an active community of local malariologists has been persistently identifying the profile of anti-malarial resistance with permanent counseling to the Brazilian Ministry of Health, which responds promptly to these evidences, changing the first line regimens [19]. As the sexual forms (which are infective for the vector) of P. falciparum generally appear later in the course of infection, opportune diagnosis and treatment tend to have a high impact on reducing the transmission intensity of this species but the same is not true for P. vivax, whose gametocytes are present in the very first days of the infection, before efficacious treatment is usually started. In 2008, 59% of all malaria cases registered in the Brazilian Amazon were treated in the first 48 h after appearance of symptoms (SIVEP-Malaria, 2009). These public health measures allied to a regularly updated online information system also impacted the number of deaths related to P. falciparum, which were not more than 58 in 2009 (Brazilian Ministry of Health, 2010). As a consequence, even in the non-indexed literature, severity due to P. falciparum is not frequently reported anymore in Brazil.

Brazil has reported 85% of its cases related to P. vivax in 2010, which puts this country in a peculiar epidemiological situation, as one of the few countries around the world with P. vivax predominance. The impact of P. vivax/P. falciparum co-infections or simultaneous circulation of both species with similar frequencies in a given population, upon the immunological status and clinical presentation of malaria is still unclear [20, 21], but most probably clinical data from population from certain areas should not be extrapolated to other areas in distinct epidemiological conditions. Actually, the lack of data on clinical presentation of P. vivax infection allied to the several particularities of this region, including the diverse genetic background of its population, implicate that the generalization of the findings from Southeast Asia may be inappropriate.

In Brazil, in 1903, the young physician Carlos Chagas (most known for the discovery of American trypanosomiasis afterwards) wrote his MD thesis on the haematological complications of malaria, which, at that moment, also occurred in the non-Amazon area. His major findings in studying P. vivax patients were severe anaemia, splenomegaly, leukopenia, cachexia and jaundice associated to concomitant staphylococcal disease [22]. Bone marrows were also analysed in these patients with no conclusive findings. Later on, during the 1940s, Djalma Batista in Manaus described a series of malarial cases from his outpatient clinics in whom large splenomegaly, cachexia and minor bleeding were frequent among those with the 'benign' tertian malaria [23]. More recently, from 1998 to 2008, 234 deaths related to vivax disease were officially reported to the Brazilian Ministry of Health [18], and an increase in the hospitalization trends for vivax patients was published in a tertiary care hospital from Manaus [24]. To complicate matters, these facts parallel a lack of robust biomarkers and specific criteria for severe disease for this species in the literature. A sine qua non requisite in the analysis of clinical severity related to P. vivax infection is the exclusion of mixed infection with P. falciparum through a more sensitive technique such as PCR and the exclusion of other co-morbidities which may be responsible for the clinical presentation per se. In the literature, in general, reports of 'complicated/severe' cases lack more precise and uniform definition criteria, in part due to the rare application of more robust endpoints such as death and admission to the intensive care unit (ICU), and therefore end up suffering bias through individual judgment of authors, editors and reviewers. As in most of the data published there were no systematic exclusion of co-morbidities and/or mono-infection confirmation using PCR, performing a meta-analysis of severe manifestations of P. vivax becomes virtually impossible. The other bias in the case of Brazil is that many relevant data are confined in abstracts from national scientific meetings and graduate students' dissertations and theses. The systematic review of these unpublished data therefore could contribute to the understanding of the clinical spectrum of vivax infection in this country and ultimately as a representative sample from Latin American vivax malaria.

Search strategy

The sources for published data on clinical aspects of vivax infection in Brazil were MEDLINE (1948 to February 2011) and LILACS (1982 to February 2011). The following search strategy was devised for both databases: (Plasmodium vivax).mp. AND (Brazil).mp. All types of study designs with primary data were included (cross-sectionals, case-controls, cohorts, case series and case reports). The abstracts were analysed in details by two independent reviewers and publications were selected if they mentioned any type of clinical complication (no specific criterion was used) in at least one patient with the diagnosis of vivax infection. Disagreement between the two reviewers was solved through consensus. Articles were excluded if they were reviews and also if they did not contain primary data on clinical aspects. For included studies, there were extracted data on date of publication, location, number of patients, and characteristics of participants (age range, pregnancy status, presence of co-morbidities), if molecular diagnosis through PCR was used to assess vivax malaria mono-infection and fatality. Exclusion criteria for analysis were participants with mixed infections (P. falciparum/P. vivax); studies in where patients with P. falciparum and P. vivax were both presented but the clinical data reported was not individualized for each species; and studies reporting the same patients from previous studies from the same authors. Through abstract analysis, 297 articles were retrieved and after application of the inclusion and exclusion criteria, 27 articles (from 1987 to 2011) were selected, which are presented in Table 1.
Table 1

Summary of publications retrieved from MEDLINE and LILACS referring to clinical aspects of P. vivax malarial patients in Brazil (1948-2011)

 

Authors

Year

of publication

Location

City (State)

PCR confirmation

Age range

(in years)

Number

of patients

Type of clinical complication

Pregnancy

Death

Co-morbidity

1

Botelho et al. [25]

1987

Cuiabá (Mato Grosso)

No

NA

41

Pulmonary manifestations

No

No

NA

2

Moura et al. [26]

1987

NA

No

NA

1

Congenital malaria (?)

No

No

NA

3

Severo et al. [27]

1994

NA

No

NA

112

Hepatitis and jaundice

No

No

NA

4

Marques et al. [28]

1996

São Paulo (São Paulo)

No

5 weeks

1

Congenital malaria and anaemia

No

No

NA

5

Siqueira-Batista et al. [29]

1998

Rio de Janeiro

(Rio de Janeiro)

No

62

1

Cardiac arrhythmia after chloroquine use

No

No

NA

6

Ventura et al. [30]

1999

Belém (Pará)

No

0-14

100

Anaemia

No

No

Hookworms and malnutrition

7

Pinheiro et al. [31]

2002

Belém (Pará)

No

NA

23

Low birth weight

Yes

No

NA

8

Jarude et al. [32]

2003

Rio Branco (Acre)

No

12-49

235

Anaemia, jaundice, hepatitis and hypoglycaemia

Yes

No

NA

9

Lacerda et al. [33]

2004

Manaus (Amazonas)

Yes

20

1

ITP

No

No

No

10

Silva et al. [34]

2004

Belém (Pará)

No

18-60

11

Blackwater fever after primaquine use

No

No

G6PD deficiency

11

Melo et al. [35]

2004

Manaus (Amazonas)

No

7-84

126

Ocular lesions

No

No

Hypovitaminosis A

12

Braga et al. [36]

2004

Fortaleza (Ceará)

No

25

1

Neurological symptoms

No

No

NA

13

Lomar et al. [37]

2005

São Paulo (São Paulo)

No

43

1

ARDS

No

No

No

14

Vermehren et al. [38]

2005

Manaus (Amazonas)

No

51

1

Acute renal failure

No

No

No

15

Braga et al. [39]

2006

Coari (Amazonas)

No

14-69

333

Hepatitis

No

No

HBV

16

Cabral et al. [40]

2006

Manaus (Amazonas)

No

4

1

Blackwater fever, anaemia and ARDS

No

No

Sickle cell anaemia

17

Lacerda et al. [41]

2007

Manaus (Amazonas)

No

23

1

Splenic hematoma

No

No

NA

18

Santana et al. [42]

2007

Manaus (Amazonas)

No

3-67

73

Methaemoglobinemia after primaquine use

No

No

G6PD deficiency

19

Lacerda et al. [43]

2008

Maués (Amazonas)

Yes

14

1

Chronic splenomegaly and thrombocytopaenia

No

No

NA

20

Ramos Jr et al. [44]

2010

Manaus (Amazonas)

No

8-39

18

Blackwater fever after primaquine use

No

No

G6PD deficiency

21

Alexandre et al. [45]

2010

Manaus (Amazonas)

Yes

0-80

17

Jaundice, anaemia, shock, acute renal failure, ARDS and haemoglobinuria

No

Yes (1)

HAV, hypertension and diabetes

22

Siqueira et al. [46]

2010

Manaus (Amazonas)

Yes

16

1

Rhabdomyolysis

No

No

No

23

Melo et al. [47]

2010

Careiro (Amazonas)

No

5-14

54

Anaemia

No

No

Intestinal helminthes

24

Andrade et al. [48]

2010

Buritis (Rondônia)

Yes

9-54

19

Jaundice, anaemia, shock, acute renal failure and ARDS

No

Yes (6)

No

25

Chagas et al. [49]

2010

Manaus (Amazonas)

No

9-44

411

Vaginal bleeding and amniorrexis

Yes

No

NA

26

Fragoso et al. [50]

2011

Manaus (Amazonas)

Yes

48

1

Hypovolaemic shock after CQ use

No

No

Hemophilia A

27

Ferreira et al. [51]

2011

Macapá (Amapá)

No

15-60

20

Methaemoglobinemia after primaquine use

No

No

G6PD deficiency

Unpublished studies were searched manually in the Annals of the Congress of the Brazilian Tropical Medicine Society (published in supplements of the indexed journal Revista da Sociedade Brasileira de Medicina Tropical [Journal of the Brazilian Society of Tropical Medicine]), from 1964 to 2011. This is the most traditional scientific event for tropical medicine clinicians in Brazil. Similar inclusion and exclusion criteria were used in this search. However if the same abstract data were published afterwards as a full paper, the published paper information was presented here. If the abstract referred to a dissertation or thesis, this more detailed information was presented instead. Forty-five abstracts were retrieved from 1995 to 2011. Of these, 17 fulfilled any of the exclusion criteria and therefore, 28 abstracts are presented in Table 2.
Table 2

Summary of abstracts referring to clinical aspects of P. vivax malarial patients published in the proceedings of the Annual Congress of the Brazilian Society of Tropical Medicine (1964-2011)

 

Authors

Year of

publication

Location City (State)

PCR confirmation

Age range

(in years)

Number

of patients

Type of clinical complication

Pregnancy

Death

Co-morbidity

1

Alecrim et al. [52]

1995

Manaus (Amazonas)

No

26

2

Splenic haematoma rupture

No

Yes (1)

NA

2

Kalmar et al. [53]

1998

São Paulo (São Paulo)

No

24

1

Pulmonary manifestations

No

No

NA

3

Sardinha et al. [54]

1998

Manaus (Amazonas)

No

42/57

2

Auto-immune anaemia induced by secondary cryoagglutinins

No

No

NA

4

Victoria et al. [55]

1998

Manaus (Amazonas)

No

21

1

ITP

No

No

NA

5

Zumpano et al. [56]

1998

Belo Horizonte

(Minas Gerais)

No

40

1

Splenic haematoma rupture

No

No

NA

6

Silva et al. [57]

2000

Manaus (Amazonas)

No

NA

25

Thombocytopaenia and bleeding

No

No

NA

7

Aragão et al. [58]

2001

Manaus (Amazonas)

No

NA

50

Thombocytopaenia and bleeding

No

No

NA

8

Evangelista et al. [59]

2002

Manaus (Amazonas)

No

< 1 month

7

Congenital malaria

(jaundice and anaemia)

No

No

NA

9

Moura et al. [60]

2002

Belo Horizonte

(Minas Gerais)

No

69

1

Acute lung oedema

No

Yes

NA

10

Park et al. [61]

2002

São Paulo (São Paulo)

No

NA

237

Thrombocytopaenia

No

No

NA

11

Viana et al. [62]

2002

Santa Inês (Maranhão)

No

21

1

Pleural effusion

No

No

NA

12

Albuquerque et al. [63]

2003

Manaus (Amazonas)

No

NA

202

Anaemia, thrombocytopaenia, blackwater fever, jaundice and bleeding

No

No

Yes (diabetes, chronic renal failure, HIV, G6PD deficiency)

13

Lacerda et al. [64]

2003

Manaus (Amazonas)

Yes

46

1

Acute lung oedema

No

Yes

NA

14

Silva et al. [65]

2003

Belém (Pará)

No

21

1

Acute lung oedema

No

No

NA

15

Silva et al. [66]

2004

Tucuruí (Pará)

No

59

1

Vasculitis

No

Yes

NA

16

Tavares et al. [67]

2004

Manaus (Amazonas)

No

12

1

Splenic haematoma

No

No

NA

17

Penna et al. [68]

2005

Belo Horizonte

(Minas Gerais)

No

52

1

Pulmonary manifestations

No

No

Yes (Dyslipidemia)

18

Mello et al. [69]

2006

Belém (Pará)

No

NA

1

Seizures and coma

No

No

NA

19

Menezes et al. [70]

2006

Manaus (Amazonas)

No

14-48

48

Abortion and premature delivery

Yes

No

NA

20

Oliveira et al. [71]

2006

Manaus (Amazonas)

No

22

1

Blackwater fever after primaquine use

No

Yes

Yes (G6PD deficiency)

21

Bastos et al. [72]

2007

Salvador (Bahia)

No

28

1

Jaundice and cholangitis

No

No

NA

22

Campos et al. [73]

2007

São Paulo (São Paulo)

No

NA

1

Splenic haematoma rupture

No

No

NA

23

Gurgel at al. [74]

2007

Manaus (Amazonas)

No

< 3 months

5

Congenital malaria (jaundice)

No

No

NA

24

Borzacov et al. [75]

2008

Porto Velho (Rondônia)

No

33

1

Acute psychosis after CQ use

No

No

NA

25

Cardoso et al. [76]

2008

Porto Velho (Rondônia)

No

57

1

Leukemoid reaction

No

No

NA

26

Ohnishi et al. [77]

2008

Belém (Pará)

No

29

1

Pulmonary manifestations

No

No

NA

27

Menezes et. al. [78]

2010

Manaus (Amazonas)

No

NA

421

Anaemia

Yes

No

NA

28

Ohnishi et al. [79]

2010

Belém (Pará)

No

> 15

83

Pulmonary manifestations and TNF and IL-12 polymorphisms

No

No

NA

Masters' dissertations and doctoral theses abstracts since 1987 were searched in the online database http://capesdw.capes.gov.br/capesdw/Teses.do maintained by the Coordination for the Improvement of Higher Education Personnel (CAPES), the institution which coordinates and supervises all the Brazilian Graduate Programmes in all areas of knowledge. The full original electronic documents were downloaded from the website when available or obtained through contact with the respective graduate students. Ten dissertations and three theses are presented in Table 3.
Table 3

Summary of master dissertations and doctoral theses retrieved from CAPES referring to clinical aspects of P. vivax malarial patients in Brazil (1948-2011)

 

Authors

Year of publication

Location City (State)

PCR confirmation

Age range (in years)

Number of patients

Type of clinical complication

Pregnancy

Death

Co-morbidity

1

Urbaez-Brito JD [80]

1995

Costa Marques (Rondônia)

No

NA

35

Jaundice

No

No

HBV

2

Alecrim MGC [81]

2000

Manaus (Amazonas)

Yes

> 18

426

Thrombocytopaenia, bleeding and DIC

No

Yes (1)

NA

3

Neves, JJO [82]

2002

Belém (Pará)

No

NA

127

Thrombocytopaenia

No

No

NA

4

Marques HO [83]

2004

Manaus (Amazonas)

No

15-75

106

Thrombocytopaenia and coagulation disorders

No

No

NA

5

Oliveira MS [84]

2004

Manaus (Amazonas)

No

0-11

69

Anaemia

No

No

Intestinal helminthes

6

Silva IBA [85]

2004

Belém (Pará)

No

> 15

83

Thormbocytopaenia and TNF

No

No

NA

7

Raposo CCBS [86]

2006

Buriticupu (Maranhão)

No

1-70

140

Jaundice, anaemia, thrombocytopaenia, acute renal failure, ARDS, bleeding and neurological symptoms

No

No

No

8

Pereira MSS [87]

2006

Manaus (Amazonas)

No

NA

76

Jaundice

Yes

No

NA

9

Guerreiro NSV [88]

2006

Macapá (Amapá)

No

25-39

35

Anaemia

No

No

NA

10

Lacerda MVG [89]

2007

Manaus (Amazonas)

Yes

> 18

142

Thrombocytopaenia and bleeding

No

No

No

11

Silva SBR [90]

2009

Cuiabá (Mato Grosso)

No

NA

397

Thrombocytopaenia

No

No

NA

12

Fragoso SCP [91]

2010

Manaus (Amazonas)

Yes

1-88

17

Autopsies series (acute lung oedema, shock, blackwater fever, spleen haematoma rupture)

No

Yes (17)

Pneumonia, G6PD deficiency, chronic hepatitis, HIV and yellow fever

13

Lança EFC [92]

2011

Manaus (Amazonas)

No

0-14

24

Anaemia, shock, ARDS, coma, jaundice, blackwater fever, metabolic acidosis and hypoglycaemia

No

Yes (2)

Malnutrition, gastroenteritis, sepsis, G6PD deficiency

Major clinical complications

Classical malaria paroxysms are typically short and sharply delineated within a period of less than eight hours. Fever is one feature that is almost invariably present during a paroxysm. Any of other common symptoms of the febrile syndrome, such as chills, rigours and sweating, are also described. These symptoms of a paroxysm could be accompanied by others, including headache, nausea and vomiting, and moderate to severe muscle, joint and back pain [93]. Indeed high fever tends to be more evident in vivax disease even with lower parasitaemia, due to its recognized lower fever-threshold (around 100 infected RBCs/microlitre) [94]. Therefore, any description of these classical symptoms, together or isolated, should be regarded by any experienced clinical as non-severe malaria, regardless of their intensity, because they are not associated to increased rates of hospitalization or fatality.

In the Brazilian literature reviewed, a wide spectrum of clinical complications aside from the classical symptoms of vivax malaria was found throughout the 68 indexed and non-indexed publications, despite the low number of deaths attributed to this species in this literature sample. The major complications are addressed as follows:

Anaemia

World Health Organization (WHO) criterion for severe anaemia is haemoglobin below 5 g/dL in children and under 7 g/dL in adults. However the clinical manifestations due to anaemia per se are not known and to what extent it contributes to the respiratory distress associated with the hyperdynamic status of the febrile syndrome. There is scarce literature on malarial anaemia in population-based studies in Latin America, as reviewed elsewhere [95]. On top of that, major differences in Latin America are seen when the same methodology is applied. That is probably related to distinct genetic background and environmental factors, e.g. in the Amazon Basin (intense racial mixture) and in the Colombian Pacific Coast (non-mixed black population) [96]. It is not known if anaemia is as frequent among patients from Brazil as in Southeast Asian patients, where P. vivax is considered to be a disease of children because the acquisition of immunity against this species occurs much faster than for P. falciparum, in highly endemic areas [97]. In Brazil only 25% of vivax disease affects children 0-14 years of age, however severe anaemia was reported in hospitalized children and adults, needing red blood cell (RBC) transfusions [45]. A key description of anaemia in vivax malaria children in Latin America was published in Venezuela in 2006 [98]. The 'congenital malaria' in newborns from the present series of reports with severe anaemia confirms previous findings that vivax malaria has an important clinical impact in children under 3 months [99]. Non-severe anaemia, however, seems to be as frequent as 25.8% among the population of a recent occupation area in Rondônia, where hydroelectric power plants are being built [100]. The cut-off of haemoglobin under 12 g/dL as a criterion of anaemia however should be seen with scepticism because of age ranges and the lack of baseline levels of haemoglobin validated to specific populations, which makes meta-analyses susceptible to misclassification. Major confounding factors in the global analysis of anaemia are the local contributors to this haematological complication such as iron-deficiency anaemia, which was found to occur in 5.6% of a rural Amazonian population, mostly among school children and women [101]. Another important associated condition, which may interfere in the comparison between distinct populations, is the prevalence of intestinal helminthic infection. In a study performed with anaemic children, the presence of hookworms and malnutrition was cited [30]. However some controversy exists regarding this influence since in a cohort study, children with any intestinal helminth were protected from anaemia triggered by acute vivax infection [47]. In fact anti-helminthic treatment and iron supplementation reduced the haematological indexes in the population from an endemic area for malaria [102]. No Brazilian study has addressed the concomitant diagnosis of parvovirus B19 as a contributing factor to anaemia in malaria, considering that recent evidence supports that the use of chloroquine (CQ) may stimulate viral replication in the bone marrow, worsening anaemia [103]. Apparently pregnant women develop anaemia as a major complication in vivax infection [32, 78], and the impact upon the concept needs further investigation. Chronic co-morbidities affecting erythrocyte physiology, such as sickle cell anaemia (SCA), may be related to more severe haemolysis and severe anaemia as well [40].

Thrombocytopaenia and other coagulation disorders

Thrombocytopaenia as defined by platelet counts under 150,000/μL seems to be very frequent among patients with vivax malaria and apparently more frequent in vivax than in falciparum patients [104], despite not being a consensus [105]. The increase in the report of thrombocytopaenia in several reference centres could also be a reflection of a better laboratorial infrastructure. Only in recent decades in developing countries automated full blood counts included platelet count as a routine. Many studies in Brazil confirm that platelet counts are directly correlated to peripheral parasitaemia [89, 90], but the meaning of this finding is still unknown. However, only mild bleeding is usually associated with this haematological complication in studies where detailed and systematic clinical description of the patients was made, even for severe thrombocytopaenia, which means in general platelet count under 50,000/μL [81, 89, 90]. In fact, there is no report in the whole literature of a fatal case of patient presenting exclusively with severe thrombocytopaenia, even for P. falciparum. That is probably why thrombocytopaenia, regardless of being described as a complication by WHO, is not strictly-speaking considered a severity criterion by itself [106]. What happens most of the time is that thrombocytopaenia is usually taken as a surrogate marker for DIC in settings where no specific examinations to confirm this severe complication are available, such as prothrombin activation time, D-dimers and fibrin degradation products. However, there is a disproportionate difference in the proportions of thrombocytopaenia, which is considered relatively frequent in large studies for frequency estimation [90] and of DIC, which is a rare complication, very scarcely reported in the literature associated to P. vivax infection [107, 108]. Actually, there is some coagulation cascade activation, but usually with minor impact on coagulation tests and platelet counts [83]. It is important to consider however that in areas where dengue is also endemic, as is the case of Brazil, thrombocytopaenia studies should obligatorily rule out this viral infection, which also presents a substantial percentage of thrombocytopaenia as part of its non-severe presentation [109]. In fact there are cases of co-infection already reported in the Brazilian Amazon recently [110], but the literature poorly describes the clinical aspects of this coincidental infection [111].

Respiratory distress and pulmonary oedema

Respiratory distress is defined by oxygen saturation less than 94%, or deep breathing (acidotic breathing), or an age-stratified increased rapid respiratory rate (> 32/min in adults, > 40 in children 5-14 y, > 50 in children aged 2 mo to 5 y, and > 60 in babies less than 2 mo)[112]. However this syndromic approach does not translate any mechanism of disease and may be associated to the clinical presentation of febrile syndrome during the malarial paroxysm, severe anaemia, metabolic acidosis, lung oedema, pneumonia or acute respiratory distress syndrome (ARDS). In most of the cited Brazilian studies, there are no described criteria on how respiratory distress was defined, which makes comparisons with the general literature impossible. Sometimes imprecise clinical presentation is simply defined as pulmonary manifestations. In only one, ARDS is well characterized, comprising detailed radiological characterization and arterial gas analysis (FiO2/PaO2) [37]. Lung oedema is usually based on clinical and radiological parameters and the effect of fluid overload is not clear for vivax infection, since only a few cases were reported so far, Brazilian cases included [39, 64, 65, 113, 114]. The impairment of respiratory symptoms after the beginning of treatment with CQ referred elsewhere [115] was not mentioned in any of the present reports, which could be due to inappropriate study design. Ruling out pneumonia is not easy because of the low frequency of positive blood cultures and due to the fact that in most of these patients with pulmonary complications empirical antibiotics are initiated as a rule. Data from the Papuan Indonesia indicate that many infants who die with P. vivax have radiological evidence of pneumonia [116], but the specificity of radiological findings to differentiate vivax-induced pulmonary abnormalities from pneumonia is questionable. In Mozambique, pyogenic bronchopneumonia was a common cause of respiratory distress in autopsied pregnant women with falciparum malaria, in both HIV positive and negative [117]. In the Amazon, HIV prevalence is estimated to be ~1% (unpublished data), which makes opportunistic diseases less prone to impact on severe clinical complications of vivax malaria, as is the case for falciparum malaria in Africa.

Neurological syndrome

This is classically the most lethal clinical complication of severe falciparum malaria and the definition is also very imprecise with a wide spectrum of possible presentations, such as: impaired consciousness or unrousable coma (Glasgow coma score ≤10 or Blantyre coma scale ≤2); prostration, i.e. generalized weakness so that the patient is unable walk or sit up without assistance; failure to feed; or multiple convulsions (more than two episodes in 24 h). Despite being infrequent in our studies, the phenomenon was also reported but not only in children [36, 86]. These reports must be very cautious in terms of ruling out other malarial complications as the cause of the neurological manifestations, such as hypoglycaemia and metabolic acidosis, but also associated infections as bacterial or viral meningoencephalitis. In India, acute intermittent porphyria was an unexpected co-morbidity associated to the neurological manifestations of patients with vivax malaria [118]. In Papua, P. vivax-associated coma was rare, occurring 23 times less frequently than that seen with falciparum malaria, and was associated with a high proportion of non-malarial causes and mixed infections detected using PCR [119].

Acute renal failure

This complication is suspected in cases of oliguria and confirmed if serum creatinine is higher than 3.0 mg/dL. Bacterial sepsis, dehydration, shock and past history of chronic renal failure should be routinely searched in the differential diagnosis. It was also reported in the Brazilian literature [38, 48], but in one study one case was found in a patient with arterial hypertension, what could be a triggering condition [45]. Despite not being frequent in Brazil, Plasmodium malariae is found in some scattered areas [120], and as a potential cause of glomerulonephritis [121], this parasite should be ruled out by molecular biology tools whenever acute renal failure is detected in a malarial patient with vivax infection, due to similarities of these two species at routine optical microscopy.

Jaundice

New WHO guidelines already point to hyperbilirubinaemia (total bilirubin > 3.0 mg/dL) as being a weak marker of severity, unless it is followed by any other vital organ dysfunction [106]. This finding seems to be the most frequent among children and adults with vivax disease considered as 'severe' [122, 123]. Since haemolysis is not usually as severe as to cause significant clinical jaundice, most of these patients actually have some hepatocyte necrosis as evidenced by the mild to moderate liver enzymes (AST/ALT) increase with subsequent cholestasis [124]. It was shown that icteric syndrome was a common cause of hospitalization in pregnant women with vivax malaria in Manaus [87]. It was also detected in newborns [59, 74], which makes vivax malaria an obligatory differential diagnosis of neonatal sepsis. Jaundice in the presence of vomiting and upper abdominal pain should raise suspicion on acalculous cholecystitis, a poorly described complication apparently with good prognosis [125]. Other diseases that may evolve to an icteric syndrome may be ruled out, especially because they are also more frequent in the tropics, such as leptospirosis [34] and typhoid fever [126, 127]. Hepatitis A virus (HAV) and vivax co-infection has already been reported as cause of jaundice and high elevation of transaminases [45]. Hepatitis B virus (HBV) is also highly prevalent in Brazil, especially in the Amazon [128] and there is some evidence that P. vivax/HBV co-infection may be related to more frequent jaundice [80] and higher transaminase levels.

Algid malaria

Algid malaria refers to the shock syndrome usually defined as circulatory collapse (systolic pressure under 70 mmHg in adults or under 50 mmHg in children) non-responsive to fluids. In the present vivax malaria reports, it was more reported most frequently among patients who died, suggesting that, as expected for this severe clinical complication, it could be regarded as a good marker of severity. However, the aetiology of this complication is still unclear even for P. falciparum. Apparently it is multifactorial and the complication should be regarded as a syndrome where cardiac dysfunction, dehydration, bleeding, adrenal insufficiency, and bacterial sepsis could all play a role [129]. A review of all malaria deaths in the USA found that 5% were due to P. vivax associated with cardiac disease [130], which suggests cardiac dysfunction as a contributing factor to algid malaria. There is robust evidence that bacteraemia in Africa is associated with higher fatality in falciparum malaria in children [131]. Less frequently shock occurs isolated, but usually as part of multi-organ dysfunction syndrome (MODS), leading to a clinical picture suggestive of 'malaria-induced toxic shock' [132].

Metabolic complications

Metabolic acidosis (plasma bicarbonate < 15 mmol/L) and hyperlactataemia (lactate > 5 mmol/L), which are common in severe falciparum malaria and are good predictors of fatal outcome, have never been described in vivax severe disease. In a series of children with vivax infection admitted to the ICU, metabolic acidosis is mentioned [92], however concomitant sepsis is described in this series and specificity for malaria cannot be assumed. If one admits lactic acidosis as a consequence of hypoxia triggered by microvasculature obstruction in falciparum disease, the scarcity of data on the frequency of this phenomenon in vivax disease may simply reflect the less severe obstruction due to less cytoadhesion, as already suggested elsewhere [133, 134]. In the case of hypoglycaemia (blood glucose < 40 mg/dL), the complication has been rarely described elsewhere [123, 135], and in only two studies in Brazil this finding was reported among children and pregnant women [32, 92].

Pregnancy-associated malaria

The impact of vivax infection upon pregnancy and the concept is less clear in Brazil and Latin America as a whole, despite robust evidence that vivax malaria causes low birth weight and maternal anaemia exists in Thailand [136] and Indonesia [137]. The burden of the infection due to this species in Brazilian pregnant women from a highly endemic area in the Amazon seems to be high [138]. Malaria anaemia in pregnant women with vivax is already known [137] and data from Brazil confirm that this is the most common complication among these women [78]. Additionally the few reports in the present series also point to low birth weight, vaginal bleeding, amniorrhexis, abortion, premature delivery, hypoglycaemia, hepatitis and jaundice as complications [31, 32, 49, 70, 87]. Hyperemesis gravidarum may superimpose to the febrile syndrome and to the gastrointestinal side effects associated to CQ in pregnant women, contributing to uncontrolled vomiting and consequent metabolic disorders. Apparently in the case of pregnancy, co-morbidities do not seem to be frequent among patients with clinical complications. Despite the need of more pathogenesis studies with the infected placenta, ultrasound studies in order to search for prognostic markers are urgently needed.

Atypical complications

Some atypical complications are not frequently described for malaria and likewise are not classically referred as severe malaria. Rhabdomyolysis has been reported for vivax in 1993 in a patient with myoadenylate deaminase deficiency [139]; only one case was reported in Brazil in a patient without co-morbidities [46]. Rarely, patients with vivax malaria could evolve with immune thrombocytopenic purpura (ITP) as a complication of the acute infection [33]. To confirm this diagnosis, the patient has to be followed up with persistent thrombocytopaenia for many weeks after the efficacious anti-malarial treatment and diseases, in which ITP is more frequently seen, such as HIV, should be discarded. The mechanisms involved are poorly understood. Splenomegaly is considered a typical finding in the physical examination of a patient with vivax disease, but the occurrence of spleen haematomas evolving with rupture and fatal outcome is relatively rare [41, 52, 91] despite being more frequent among this species as compared to falciparum [140]. In any case, patients with vivax malaria referring abdominal pain should be investigated for this complication as some patients may evolve with a bad prognosis if not properly managed by a surgeon. Ocular manifestations in vivax disease apparently have no relation to cerebral malaria or bad prognosis, as is the case for falciparum [141]. Few reports have been published on vivax patients with non-severe disease and retinal haemorrhage [142] and in Brazil this fundoscopical finding was associated with hypovitaminosis A [35]. Another atypical complication, which may be more frequent than expected for vivax infection, and with outstanding impact upon the development of some emerging economies in the globe, is poor school performance which should be a surrogate marker for the intellectual impairment related to malaria [143]. Acute malnutrition has been shown to be a complication of vivax malaria in highly endemic areas [144]. In Brazil a few evidences show that malnourishment and vivax co-exist but the impact of this association is still unknown [145]. In only two studies was malnutrition referred to as a possible cause of the reported clinical complication [92, 146]. Vasculitis [66], leukemoid reaction [76] and pleural effusion [62] as a marker of severity seems to be speculative and details of these reports do not support any in-depth analysis.

Other aspects

High parasite density as a marker of severity for P. vivax, as it is for P. falciparum, still needs additional studies, considering this parasite infects preferably reticulocytes. The same occurs with the presence of schizonts in peripheral blood, which is usually associated with high sequestered biomass and severity for falciparum [147], but is still an unexplored aspect for vivax. Strong linear trends were identified regarding increasing plasma levels of C reactive protein (CRP) and the gradation of disease severity [48]. Super-oxide dismutase-1 (SOD-1) seems to be a powerful predictor of disease severity in individuals with different clinical presentations of vivax malaria [148].

As soon as precise markers of severity are available, it would be possible to design studies powered to analyse the influence of the host genetics in the development of severe vivax disease. Some association between pulmonary manifestations and TNF and IL-12 polymorphisms has been attempted [79]. It has been proposed for the first time in Manaus that G6PD deficiency could protect against vivax malaria, in a cross-sectional study, based on past history of the enrolled population [149]. This protection was later confirmed in Pakistan [150]. Male hemizygotes for this deficiency also showed to be protected against severe falciparum malaria [151]. No data exist on the protection against severe vivax disease. Likewise, people with the FYA/FYB genotype presented higher susceptibility to clinical vivax malaria [152]. Since the discovery in Brazil that Duffy-negative individuals could be infected by P. vivax[153], some speculation on the other possible invasion receptors has emerged. However, cohort studies are needed to investigate the real impact of the distinct Duffy genotypes on clinical malaria incidence, submicroscopic asymptomatic infection, malaria-triggered anaemia and lower parasitaemia, as already suggested for FYB/FYX and FYA/FYX genotypes in the Brazilian Amazon [154].

Advances in pathogenic mechanisms

The major advance in the study of the pathogenesis of severe vivax disease was the demonstration of P. vivax-infected RBCs cythoadhesion on human lung endothelial cells (HLEC) and placental tissue ex vivo[134]. This cythoadhesion was obviously lower than P. falciparum-infected RBCs adhesion, but with similar stability. However the next challenge is to try to link this finding to the in vivo phenomena [155]. The increased adhesion with the addition of LPS in the P. vivax ex vivo model suggests that endothelial activation may be an enhancing event. The role of augmented platelet-derived microparticles [156] and CD4+CD25+FoxP3+ regulatory T cells (Tregs) cells found in vivax disease should also be investigated in severe disease. Plasma levels of TNF, IFN-γ and also IFN-γ/IL-10 ratios were increased and exhibited a linear trend with gradual augmentation of disease severity [48]. Patients with severe disease also presented higher haemolysis and higher plasma concentrations of Cu/Zn SOD-1 and lower concentrations of PGE-2 and TGF-β than those with mild disease [157]. Oxidative stress was also proposed as a mechanism for thrombocytopaenia found in vivax disease [158, 159], as well as its association with TNF [85]. Circulating immune complexes were not associated to vivax thrombocytopaenia [89], but polymorphisms of the highly immunogenic AMA-1 were associated to platelet count in these patients [160], suggesting that immunological mechanisms are involved in platelet destruction. In the case of anaemia, there is no correlation between the presence of anti-erythrocyte and anti-cardiolipin antibodies and the presence or intensity of this haematological finding [161]. Auto-immunity induced by secondary cryoagglutinins should be explored [54]. Erythropoiesis seems to be affected [162], and the finding of parasites inside the bone marrow [43] stimulate the search for mechanisms of diserythropoiesis in this milieu, despite technical limitations to analyse this tissue in humans. The role of the spleen in severe disease is still unknown, as well as the role of the variant subtelomeric multigene vir family, which may influence the sequestration of infected RBCs in this organ [163]. Parasite genetics, such as MSP-1 and CSP polymorphisms, has not been shown to be associated with clinical severity [164].

In summary, the immune response in patients with severe vivax disease has not been fully addressed in the general literature, and further approaches are needed in order to unveil immune mechanisms related to these complications.

Vivax malaria therapy concerns

In terms of therapy, CQ and primaquine (PQ) are still the drugs of choice for the treatment of vivax malaria in many endemic areas, Brazil included. It is important however to keep in mind that side effects of these drugs could be erroneously taken as clinical severity associated to the parasite infection. In the case of CQ, it is considered a safe drug, despite the occurrence of pruritus, which most of the time is considered to be a minor effect and rarely requires the drug withdrawal [165]. Psychosis on the other hand is a more severe complication [75, 166], as well as cardiac arrhythmia [29]. Atypical complications of its use such as severe gastric bleeding were associated with haemophilia A [50]. In the case of PQ, tranquillity is not the same as with CQ, because PQ is able to induce metahaemoglobinaemia [42, 51] and severe haemolysis [44] in patients with G6PD deficiency. The burden of the deficiency in Brazil is poorly measured but the few data available in endemic areas for malaria has shown it to be between 3.0% [149] and 5.8% [167] among men, since the deficiency is linked to the X-chromosome. In the case of Brazil, the prescription of PQ in the abbreviated regimen (0.5 mg/kg/day for 7 days) without any routine G6PD screening may contribute to increase the frequency and severity of the side effects triggered by this drug, as confirmed by the reports of patients with blackwater fever after PQ use, including one fatal case [63, 71, 91, 92, 168]. To complicate matters, for the radical cure, the new drug under late stage clinical investigation, tafenoquine, shows no evidence that it is safer than PQ in G6PD deficient [169].

The simultaneous occurrence of severe vivax disease and CQ-resistance in some countries has raised the question of a possible association between severity and resistance, especially for anaemia [170]. CQ resistance actually has been reported in Brazil almost at the same time as clinical severity [171, 172], but some studies argue against that, showing that severe patients responded to CQ [45]. Added to that, reliable genetic markers of resistance are lacking [173]. Increased levels of pvmdr-1 and pvcrt-o RNA in a single severe patient with vivax malaria however paved the way to the study of gene expression in association to resistance [174].

As suggested by the present data, 11 cases were reported in Brazilian travellers who live in the non-endemic area and occasionally go to the Amazon. Regarding the possibility of severe disease triggered by P. vivax, Travel Outpatient Clinics should emphasize to their clients the possible complications of this disease, still considered 'benign' in most of the educational folders and travellers' guides, especially because no good chemoprophylaxis against relapses related to this species is available to date. On top of that, retarded diagnosis and treatment outside the Amazon area contributes to the higher fatality rate of P. falciparum patients [18]. A similar situation could be observed for P. vivax, being this disease misdiagnosed as other febrile diseases.

Despite the increasing evidence of CQ-resistance worldwide, the Brazilian Ministry of Health still recommends CQ as the first line therapy for vivax treatment, considering that only one single study has properly shown ~10% of resistance in the area of Manaus [172]. The few available efficacy studies on ACT for the treatment of vivax were reviewed recently [175], and give good evidence for their use in vivax malaria, however, more studies are needed. Only recently the Brazilian Ministry of Health followed the WHO recommendations to manage vivax severe patients with parenteral artemisinin derivatives as if they had severe falciparum infection, considering that a submicroscopic mixed infection could be misdiagnosed in the routine TBS [106]. This recommendation was already stated by the famous Brazilian parasitologist Samuel Pessôa in his Medical Parasitology textbook, from 1967 [176]. Supportive therapy is even more neglected and there is virtually no study focusing in the clinical management of patients with severe vivax disease.

Research priorities

There are actually many priorities in clinical research related to vivax disease. The major ones were discussed previously. Considering that asymptomatic infections due to P. vivax are even more common in endemic areas for both species [177], the likelihood of an asymptomatic patient becoming ill due to another microorganism is not improbable, which requests a good epidemiological characterization of the endemic area where the severe cases are being reported and systematic exclusion of mixed infections through PCR, due to the possibility of submicroscopic infection with P. falciparum. Another major priority in vivax research is the investigation of concurrent infections through systematic laboratory exclusion of the most prevalent infectious diseases in severe patients. In Figure 1, the major research questions are addressed.
https://static-content.springer.com/image/art%3A10.1186%2F1475-2875-11-12/MediaObjects/12936_2011_Article_1954_Fig1_HTML.jpg
Figure 1

Major research priorities in the study of severe vivax disease.

Conclusions

In the present systematic review, the major limitation was the fact that most of the information was retrieved from non-peer reviewed sources. However, it seems clear that vivax patients in Brazil are calling the attention of their physicians only recently. Like other infectious diseases, defining severity criteria is a major challenge. As an example, dengue fever specialists have defined 'warning signs' for dengue haemorrhagic fever, the most lethal complication of the infection due to dengue virus, which are early signs that should raise the suspicion of severe dengue but are not applied themselves to the final classification [178] as proper intervention can avoid the patient evolving to more severe stages. Sometimes in the literature potential 'warning signs' for severe vivax malaria are mistaken for severity criteria, which are those ultimately related to increased fatality. WHO severity criteria formerly developed for falciparum disease seem to apply reasonably to vivax disease as well, but there are clearly 'warning signs' that should motivate clinicians from the tropics to observe patients more closely, such as isolated thrombocytopaenia, isolated jaundice or the presence of chronic or acute co-morbidities. For example, during influenza outbreaks, the virus does not necessarily kill per se, but compromises the most vulnerable population and facilitates fatal secondary bacterial infections. The most common complications observed in the field are not necessarily the most frequently reported in the literature, sometimes biased by the uniqueness or exoticness of the cases reported. It is only after 1987 that these cases started to be reported in Brazil in indexed and non-indexed publications, which may simply parallel the increase in the absolute numbers of vivax cases in Brazil, culminating in the more frequent observation of rare clinical events triggered by this parasite. Publication bias may also impact the chronology of these complicated case reports, especially when research group leaderships based in the endemic areas start to look for clinical aspects more closely. It is noteworthy however that studies on pathogenesis must be careful when dealing with severe vivax disease as a single entity. The best approach is to study groups of patients with specific complications (e.g., severe anaemia or ARDS) in order to minimize the risk of heterogeneous groups with probable multifactor causality, including the diversity of host genetics. The amount of complications related to anti-malarial drug use is not negligible, especially primaquine. Multicentric studies using standard protocols, with the proper care of confirming mono-infection by more specific tools (e.g. PCR) and ruling out co-morbidities, are urgently needed to characterize the real spectrum of vivax disease worldwide. Tissues from deceased patients are also waited, in order to support more robust analyses of the mechanisms of death. Without that information, vaccine clinical trials against P. vivax will not be able to include among their endpoints the protection against the severe disease (essentially severe anaemia), which parallels the frequency of severe falciparum anaemia in some endemic areas. The recent discussion on malaria eradication will only succeed if the two parasites which most affect humans begin to be treated as distinct and not causing a single disease. Clinical characterization is the first step to estimate its burden and ultimately to plan any control strategy in the near future.

Abbreviations

ACT: 

Artemisinin-Combination Therapy

AMA: 

Apical Membrane Antigen

API: 

Annual Parasite Incidence

ARDS: 

Acute Respiratory Distress Syndrome

CAPES: 

Coordination for the Improvement of Higher Education Personnel

CQ: 

Chloroquine

CRP: 

C-Reactive Protein

CSP: 

Circumsporozoite Protein

DIC: 

Disseminated Intravascular Coagulation

G6PD: 

Glucose-6-Phosphate-Dehydrogenase

HAV: 

Hepatitis A Virus

HBV: 

Hepatitis B Virus

HLEC: 

Human Lung Endothelial Cell

ICU: 

Intensive Care Unit

IL: 

Interleukin

INF: 

Interferon

ITP: 

Immune Thrombocytopenic Purpura

MODS: 

Multi-Organ Dysfunction Syndrome

MSP: 

Merozoite Surface Protein

PCR: 

Polymerase-Chain Reaction

PQ: 

Primaquine

RBC: 

Red Blood Cell

SCA: 

Sickle Cell Anaemia

SIVEP-Malaria: 

Epidemiological Surveillance Information System for Malaria

SOD: 

Superoxide dismutase

TBS: 

Thick Blood Smear

TGF: 

Tumor Growth factor

TNF: 

Tumor Necrosis Factor

Declarations

Acknowledgements

We acknowledge the organizers of the 47th Congress of the Brazilian Society of Tropical Medicine, held in Natal (Rio Grande do Norte) on 23-26 March, 2011, especially its President Dr. Kleber Luz, for embracing and supporting the 1st Brazilian Workshop on Severe P. vivax as part of its official programme, from whose reflections this review was written. The workshop was supported by the PRONEX Malaria Network, funded by the Brazilian Ministry of Science and Technology (MCT), National Council for Scientific and Technological Development (CNPq), Brazilian Ministry of Health (DECIT/SCTIE/MS) and the Research Support Foundations from the states (FAPEAM, FAPERJ, FAPESP, FAPEPA, FAPEMAT, FAPEMIG). MVGL is a level 2 productivity fellow from CNPq.

Authors’ Affiliations

(1)
Fundação de Medicina Tropical Dr. Heitor Vieira Dourado
(2)
Universidade do Estado do Amazonas
(3)
Universidade Nilton Lins
(4)
Instituto Leônidas e Maria Deane
(5)
Fundação Oswaldo Cruz
(6)
Instituto Evandro Chagas
(7)
Instituto de Pesquisas em Patologias Tropicais
(8)
Secretaria de Saúde do Amapá
(9)
Universidade Federal do Maranhão
(10)
Universidade Federal do Acre

References

  1. Mendis K, Sina BJ, Marchesini P, Carter R: The neglected burden of Plasmodium vivax malaria. Am J Trop Med Hyg. 2001, 64: 97-106.PubMedGoogle Scholar
  2. Mendes C, Dias F, Figueiredo J, Mora VG, Cano J, de Sousa B, do Rosario VE, Benito A, Berzosa P, Arez AP: Duffy negative antigen is no longer a barrier to Plasmodium vivax-molecular evidences from the African West Coast (Angola and Equatorial Guinea). PLoS Negl Trop Dis. 2011, 5: e1192PubMed CentralPubMedGoogle Scholar
  3. Guerra CA, Howes RE, Patil AP, Gething PW, Van Boeckel TP, Temperley WH, Kabaria CW, Tatem AJ, Manh BH, Elyazar IR, Baird JK, Snow RW, Hay SI: The international limits and population at risk of Plasmodium vivax transmission in 2009. PLoS Negl Trop Dis. 2010, 4: e774PubMed CentralPubMedGoogle Scholar
  4. Mueller I, Galinski MR, Baird JK, Carlton JM, Kochar DK, Alonso PL, del Portillo HA: Key gaps in the knowledge of Plasmodium vivax, a neglected human malaria parasite. Lancet Infect Dis. 2009, 9: 555-566.PubMedGoogle Scholar
  5. Price RN, Tjitra E, Guerra CA, Yeung S, White NJ, Anstey NM: Vivax malaria: neglected and not benign. Am J Trop Med Hyg. 2007, 77: 79-87.PubMed CentralPubMedGoogle Scholar
  6. Lacerda MVG, Zackiewicz C, Alecrim WD, Alecrim MGC: The neglected Plasmodium vivax: are researchers from endemic areas really concerned about new treatment options?. Rev Soc Bras Med Trop. 2007, 40: 489-490.PubMedGoogle Scholar
  7. Kochar DK, Saxena V, Singh N, Kochar SK, Kumar SV, Das A: Plasmodium vivax malaria. Emerg Infect Dis. 2005, 11: 132-134.PubMed CentralPubMedGoogle Scholar
  8. Tjitra E, Anstey NM, Sugiarto P, Warikar N, Kenangalem E, Karyana M, Lampah DA, Price RN: Multidrug-resistant Plasmodium vivax associated with severe and fatal malaria: a prospective study in Papua, Indonesia. PLoS Med. 2008, 5: e128PubMed CentralPubMedGoogle Scholar
  9. Rogerson SJ, Carter R: Severe vivax malaria: newly recognised or rediscovered. PLoS Med. 2008, 5: e136PubMed CentralPubMedGoogle Scholar
  10. Reiter P: From Shakespeare to Defoe: malaria in England in the Little Ice Age. Emerg Infect Dis. 2000, 6: 1-11.PubMed CentralPubMedGoogle Scholar
  11. Austin SC, Stolley PD, Lasky T: The history of malariotherapy for neurosyphilis. Modern parallels. JAMA. 1992, 268: 516-519.PubMedGoogle Scholar
  12. Picot S: Is Plasmodium vivax still a paradigm for uncomplicated malaria?. Med Mal Infect. 2006, 36: 406-413.PubMedGoogle Scholar
  13. Galinski MR, Barnwell JW: Plasmodium vivax: who cares?. Malar J. 2008, 7 (Suppl 1): S9PubMed CentralPubMedGoogle Scholar
  14. Bassat Q, Alonso PL: Defying malaria: Fathoming severe Plasmodium vivax disease. Nat Med. 2011, 17: 48-49.PubMedGoogle Scholar
  15. WHO: World Malaria Report 2010. 2010Google Scholar
  16. Saraiva MG, Amorim RD, Moura MA, Martinez-Espinosa FE, Barbosa MG: Urban expansion and spatial distribution of malaria in the municipality of Manaus, State of Amazonas. Rev Soc Bras Med Trop. 2009, 42: 515-522.PubMedGoogle Scholar
  17. Gonçalves MJF, Alecrim WD: Non-planed urbanization as a contributing factor for malaria incidence in Manaus-Amazonas, Brazil. Rev Salud Publica (Bogota). 2004, 6: 156-166.Google Scholar
  18. Oliveira-Ferreira J, Lacerda MV, Brasil P, Ladislau JL, Tauil PL, Daniel-Ribeiro CT: Malaria in Brazil: an overview. Malar J. 2010, 9: 115PubMed CentralPubMedGoogle Scholar
  19. Gama BE, Lacerda MV, Daniel-Ribeiro CT, Ferreira-da-Cruz MF: Chemoresistance of Plasmodium falciparum and Plasmodium vivax parasites in Brazil: consequences on disease morbidity and control. Mem Inst Oswaldo Cruz. 2011, 106 (Suppl 1): 159-166.PubMedGoogle Scholar
  20. Genton B, D'Acremont V, Rare L, Baea K, Reeder JC, Alpers MP, Muller I: Plasmodium vivax and mixed infections are associated with severe malaria in children: a prospective cohort study from Papua New Guinea. PLoS Med. 2008, 5: e127PubMed CentralPubMedGoogle Scholar
  21. Maitland K, Williams TN, Bennett S, Newbold CI, Peto TE, Viji J, Timothy R, Clegg JB, Weatherall DJ, Bowden DK: The interaction between Plasmodium falciparum and P. vivax in children on Espiritu Santo island, Vanuatu. Trans R Soc Trop Med Hyg. 1996, 90: 614-620.PubMedGoogle Scholar
  22. Chagas C: Hematological studies of impaludism. MD Thesis. 1903, Manguinhos InstituteGoogle Scholar
  23. Batista D: The paludisme in the Amazon: a contribution to epidemiology, protozoology and clinics, study about the billiary-hemoglobinuric fever. 1946, Rio de Janeiro: Imprensa NacionalGoogle Scholar
  24. Santos-Ciminera PD, Roberts DR, Alecrim MG, Costa MR, Quinnan GV: Malaria diagnosis and hospitalization trends, Brazil. Emerg Infect Dis. 2007, 13: 1597-1600.PubMed CentralPubMedGoogle Scholar
  25. Botelho C, Guedes Barbosa LS, Aquino JL, Silva MD, Meirelles SM, Jardim JR: Respiratory manifestations in Plasmodium falciparum and vivax malaria. Rev Inst Med Trop Sao Paulo. 1987, 29: 337-345.PubMedGoogle Scholar
  26. Moura EFA, Kawachi J, Mattos MNR, Cavalcante RS, Duarte AN: Neonatal malaria: report of a case. J Pediatr (Rio J). 1987, 62: 279-280.Google Scholar
  27. Severo V, Severo MMS, Behar PR, Dossin TJ: Laboratory profile of malarial patients. J Bras Med. 1994, 67: 141-154.Google Scholar
  28. Marques HH, Vallada MG, Sakane PT, Boulos M: Congenital malaria: case reports and brief review of literature. J Pediatr (Rio J). 1996, 72: 103-105.Google Scholar
  29. Siqueira-Batista R, Ramos AN, Pessanha BS, Sforza-de-Almeida MP, Potsch DF: Chloroquine and cardiac arrhythmia: case report. East Afr Med J. 1998, 75: 117-119.PubMedGoogle Scholar
  30. Ventura AMRS, Pinto AYN, Silva RSU, Calvosa VSP, Silva Filho MG, Souza JM: Plasmodium vivax malaria in children and adolescents - epidemiological, clinical and laboratory features. J Pediatr (Rio J). 1999, 75: 187-194.Google Scholar
  31. Pinheiro MCN, Branco E, Barata ACS, Dantas RTS, Fernandes WCS: Malaria during the pregnancy and low birth weight from endemic areas in the Amazon. Rev Para Med. 2002, 16: 25-28.Google Scholar
  32. Jarude R, Trindade R, Tavares-Neto J: Malaria in pregnant women of a public maternity of Rio Branco (Acre State, Brazil). Rev Bras Ginecol Obstet. 2003, 25: 149-154.Google Scholar
  33. Lacerda MV, Alexandre MA, Santos PD, Arcanjo AR, Alecrim WD, Alecrim MGC: Idiopathic thrombocytopenic purpura due to vivax malaria in the Brazilian Amazon. Acta Trop. 2004, 90: 187-190.PubMedGoogle Scholar
  34. Srinivas R, Agarwal R, Gupta D: Severe sepsis due to severe falciparum malaria and leptospirosis co-infection treated with activated protein C. Malar J. 2007, 6: 42PubMed CentralPubMedGoogle Scholar
  35. Melo AM, de Carvalho RA, Figueiredo JF, Vannucchi H, Jordao A, Rodrigues ML: Serum vitamin A levels in patients with ocular lesions attributable to non-complicated malaria in the Brazilian Amazon region. Trans R Soc Trop Med Hyg. 2004, 98: 485-488.PubMedGoogle Scholar
  36. Braga MD, Alcantara GC, Silva CN, Nascimento CG: Cerebral malaria in Ceara: a case report. Rev Soc Bras Med Trop. 2004, 37: 53-55.PubMedGoogle Scholar
  37. Lomar AV, Vidal JE, Lomar FP, Barbas CV, Matos GJ, Boulos M: Acute respiratory distress syndrome due to vivax malaria: case report and literature review. Braz J Infect Dis. 2005, 9: 425-430.PubMedGoogle Scholar
  38. Vermehren R, Cardoso AD, Bulbol WS, Franco M, Coelho K, Lorenzi F, Nunes V, Gonçalves J: Report of a case of acute renal failure in Plasmodium vivax malaria. J Bras Nefrol. 2005, 27:Google Scholar
  39. Curlin ME, Barat LM, Walsh DK, Granger DL: Noncardiogenic pulmonary edema during vivax malaria. Clin Infect Dis. 1999, 28: 1166-1167.PubMedGoogle Scholar
  40. Cabral PHO, Andrade SD, Alecrim WD, Alecrim MGC, Lacerda MVG: Malaria and sickle cell anemia: report of complications and clinical management of three patients in a highly endemic area for Plasmodium vivax malaria in the Brazilian Amazon. Case Rep Clin Pract Rev. 2006, 7: 220-223.Google Scholar
  41. Lacerda MVG, Oliveira SL, Alecrim MGC: Splenic hematoma in a patient with Plasmodium vivax malaria. Rev Soc Bras Med Trop. 2007, 40: 96-97.PubMedGoogle Scholar
  42. Santana MS, Rocha MA, Arcanjo AR, Sardinha JF, Alecrim WD, Alecrim MGC: Association of methemoglobinemia and glucose-6-phosphate dehydrogenase deficiency in malaria patients treated with primaquine. Rev Soc Bras Med Trop. 2007, 40: 533-536.PubMedGoogle Scholar
  43. Lacerda MV, Hipolito JR, Passos LN: Chronic Plasmodium vivax infection in a patient with splenomegaly and severe thrombocytopenia. Rev Soc Bras Med Trop. 2008, 41: 522-523.PubMedGoogle Scholar
  44. Ramos WM, Sardinha JF, Costa MR, Santana MS, Alecrim MG, Lacerda MV: Clinical aspects of hemolysis in patients with P. vivax malaria treated with primaquine, in the Brazilian Amazon. Braz J Infect Dis. 2010, 14: 410-412.Google Scholar
  45. Alexandre MA, Ferreira CO, Siqueira AM, Magalhaes BL, Mourao MPG, Lacerda MVG, Alecrim MGC: Severe Plasmodium vivax Malaria, Brazilian Amazon. Emerg Infect Dis. 2010, 16: 1611-1614.PubMed CentralPubMedGoogle Scholar
  46. Siqueira AM, Alexandre MA, Mourao MP, Santos VS, Nagahashi-Marie SK, Alecrim MG, Lacerda MV: Severe rhabdomyolysis caused by Plasmodium vivax malaria in the Brazilian Amazon. Am J Trop Med Hyg. 2010, 83: 271-273.PubMed CentralPubMedGoogle Scholar
  47. Melo GC, Reyes-Lecca RC, Vitor-Silva S, Monteiro WM, Martins M, Benzecry SG, Alecrim MG, Lacerda MV: Concurrent helminthic infection protects schoolchildren with Plasmodium vivax from anemia. PLoS ONE. 2010, 5: e11206PubMed CentralPubMedGoogle Scholar
  48. Andrade BB, Reis-Filho A, Souza-Neto SM, Clarencio J, Camargo LM, Barral A, Barral-Netto M: Severe Plasmodium vivax malaria exhibits marked inflammatory imbalance. Malar J. 2010, 9: 13PubMed CentralPubMedGoogle Scholar
  49. Chagas EC, Nascimento CT, Santana Filho FS, Botto-Menezes CH, Martinez-Espinosa FE: Impact of malaria during pregnancy in the Amazon region. Rev Panam Salud Publica. 2009, 26: 203-208.PubMedGoogle Scholar
  50. Fragoso SC, Alexandre MA, Santos PJ, Mourao MP, Passos LN, Magalhaes BM, Siqueira AM, Lacerda MV: Hypovolaemic shock triggered by P. vivax infection in a patient with mild haemophilia A. Haemophilia. 2011, 17: 159-160.PubMedGoogle Scholar
  51. Ferreira ME, Gomes MD, Vieira JL: Methemoglobinemia in patients with Plasmodium vivax receiving oral therapy with primaquine. Rev Soc Bras Med Trop. 2011, 44: 113-115.PubMedGoogle Scholar
  52. Alecrim MGC, Silva VMQ, Melo MD, Araújo JR, Guerra MVF, Silva NB, Ferreira LCL, Silva EB, Alecrim WD: Splenic rupture in malarial patients from the Instituto de Medicina Tropical de Manaus [abstract]. Rev Soc Bras Med Trop. 1995, 28: 151Google Scholar
  53. Kalmar EMN, Cassetari V, Machado FR, Alencar F, Kirchgatter K, Boulos M, Tapajós R: Severe malaria in patient with Plasmodium vivax infection: a case report [abstract]. Rev Soc Bras Med Trop. 1998, 31: 56Google Scholar
  54. Sardinha YF, Nunes SB, Albuquerque SRL, Marques HO, Passos LNM: Hemolytic anemia due to secondary cryoagglutinins and P. vivax malaria: report of two cases [abstract]. Rev Soc Bras Med Trop. 1998, 31: 144Google Scholar
  55. Victoria MB, Victoria F, Coellho AHV, Santos LO, Alecrim MGC: Thrombocytopenic purpura in patient with Plasmodium vivax malaria: case report [abstract]. Rev Soc Bras Med Trop. 1998, 31: 55Google Scholar
  56. Zumpano JF, Queiroz JN, Rocha MOC: Spontaneous splenic rupture in vivax malaria [abstract]. Rev Soc Bras Med Trop. 1998, 31: 46Google Scholar
  57. Silva SL, Santana Filho FS, Arcanjo ARL, Alecrim WD, Alecrim MGC: Clinical and hematological profile of hospitalized patients with vivax malaria and thrombocytopenia in the Fundação de Medicina Tropical do Amazonas, from January 2007 to September 1999 [abstract]. Rev Soc Bras Med Trop. 2000, 33: 348Google Scholar
  58. Aragão PS, Alecrim MGC, Evangelista NMA, Tavares AM, Santana Filho FS, Alecrim WD: Clinical and laboratorial study on Plasmodium vivax malaria [abstract]. Rev Soc Bras Med Trop. 2001, 34: 341Google Scholar
  59. Evangelista NMA, Aragão DS, Tavares AM, Magalhães L, Alexandre MAA, Alecrim MGC, Alecrim WD: Neonatal malaria due to Plasmodium vivax in the Fundação de Medicina Tropical do Amazonas [abstract]. Rev Soc Bras Med Trop. 2002, 35: 344Google Scholar
  60. Moura ACL, Balbo BEP, Cancela ALE, Betti MH, Heneine RAD, Zumpano JF: Death due to P. vivax in a non-endemic area [abstract]. Rev Soc Bras Med Trop. 2002, 35: 369Google Scholar
  61. Park CHL, Ferreira CB, Bianchi CP, Fazio FS, Costa JC, Padilha ARS, Fonseca MO, Boulos M: Thrombocytopenia in patients with Plasmodium vivax malaria [abstract]. Rev Soc Bras Med Trop. 2002, 35: 370Google Scholar
  62. Viana GMC, Monteiro PS, Nascimento MDSB, Burarttini MN: Severe malaria due to P. vivax: case report [abstract]. Rev Soc Bras Med Trop. 2002, 35: 367Google Scholar
  63. Albuquerque BC, Couto BB, Moraes TC, Couto S: The relevance of clinical and laboratorial aspects in patients with Plasmodium vivax malaria hospitalized in the Fundação de Medicina Tropical do Amazonas, 2002 [abstract]. Rev Soc Bras Med Trop. 2003, 36: 280Google Scholar
  64. Lacerda MVG, Manso MRC, Ferreira LCL, Silva FM, Santos PJT, Alecrim WD, Alecrim MGC: Patient with vivax malaria and acute lung edema in the Brazilian Amazon: case report and literature review [abstract]. Rev Soc Bras Med Trop. 2003, 36: 281Google Scholar
  65. Silva IBA, Araújo JR, Cleonardo A, Ventura AM, Pinto AY, Linonati RMF, Silva Filho M, Valente MIA, Castro JAA, Souza JM: Severe vivax malaria and non-cardiogenic pulmonary edema [abstract]. Rev Soc Bras Med Trop. 2003, 36: 273Google Scholar
  66. Silva IBA, Carneiro MS, Araújo JR, von Mühler CA, Souza JM: Vivax malaria and vasculitis: case evolving with death [abstract]. Rev Soc Bras Med Trop. 2004, 37: 275Google Scholar
  67. Tavares AM, Tavares AM, Cavalcante CP: Splenic subcapsullary hematoma in patient with Plasmodium vivax malaria [abstract]. Rev Soc Bras Med Trop. 2004, 37: 270Google Scholar
  68. Penna J, Zumpano JF, Penna L, Rocha MOC: Case report: pulmonary manifestations of Plasmodium vivax malaria [abstract]. Rev Soc Bras Med Trop. 2005, 38: 379Google Scholar
  69. Mello GS, Mello Filho GB, Rodrigues DCH: Malarial coma due to Plasmodium vivax [abstract]. Rev Soc Bras Med Trop. 2006, 39: 106Google Scholar
  70. Menezes CHAB, Martinez-Espinosa FE, Ferreira LCL, Simplicio JL, Frota AC: Effects of malarial infection on the course of pregnancy and fetus in patients from the Fundação de Medicina Tropical do Amazonas [abstract]. Rev Soc Bras Med Trop. 2006, 39: 107Google Scholar
  71. Oliveira RSM, Santos VS, Lacerda MVG, Alecrim WD: Hemolysis associated to acute renal failure in an immunocompetent patient with G6PD deficiency and vivax malaria: case report with favourable evolution [abstract]. Rev Soc Bras Med Trop. 2006, 39: 109Google Scholar
  72. Bastos CJC, Mascarenhas-Batista AV, Freire M, Amorim F, Andrade M, Gomes E: Severe malaria due to Plasmodium vivax: case report [abstract]. Rev Soc Bras Med Trop. 2007, 40: 146Google Scholar
  73. Campos LRP, Mascheretti M, Brasil RA, Duarte MIS: Evaluation of splenic immune response in patient infected with Plasmodium vivax [abstract]. Rev Soc Bras Med Trop. 2007, 40: 141Google Scholar
  74. Gurgel RL, Coutinho LI, Su WCS, Lacerda MVG: Clinical manifestations of congenital vivax malaria in the Western Brazilian Amazon [abstract]. Rev Soc Bras Med Trop. 2007, 40: 147Google Scholar
  75. Borzacov LMP, Cardoso GA, Siqueira GD, Cardoso LAP, Barbieri AB, Fontes CJF: Acute psychosis induced by chloroquine during vivax malaria treatment [abstract]. Rev Soc Bras Med Trop. 2008, 41: 221Google Scholar
  76. Cardoso GA, Siqueira GD, Borzacov LMP, Tristão FR, Cardoso LAP, Fontes CJF: Leukemoid reaction caused by Plasmodium vivax: case report [abstract]. Rev Soc Bras Med Trop. 2008, 41: 221Google Scholar
  77. Ohnishi MDO, Ventura AM, Linonati RMF, Mendes MM, Apolinário JHD, Souza JM: The lung in vivax malaria: case report [abstract]. Rev Soc Bras Med Trop. 2008, 41: 215Google Scholar
  78. Menezes CHAB, Silva SCL, Farias LSR, Bacelar BRB, Bardaji A, Meghna D, Martinez-Espinosa FE: Prevalence of anemia and Plasmodium vivax infection in routine antenatal attention in a primary care center in the City of Manaus [abstract]. Rev Soc Bras Med Trop. 2010, 43: 215Google Scholar
  79. Ohnishi MDO, Linonati RMF, Silva AF, Santos SEB, Ventura AM, Souza JM: Pulmonary manifestations in patients infected with Plasmodium vivax and correlation with TNF-alfa and IL-12 polymorphisms [abstract]. Rev Soc Bras Med Trop. 2010, 43: 84Google Scholar
  80. Urbaez-Brito JD: Clinical and laboratorial characteristics of human malaria and hepatitis B virus association. Master Dissertation. 1995, University of Brasília, Tropical Medicine DepartmentGoogle Scholar
  81. Alecrim MGC: Clinical aspects, resistance and parasitary polymorphism of Plasmodium vivax malaria in Manaus. PhD Thesis. 2000, University of Brasília, Tropical Medicine DepartmentGoogle Scholar
  82. Neves JJO: Malaria in Pará: study of the clinical and laboratorial picture in infections caused by Plasmodium vivax. Master Dissertation. 2002, Federal University of ParáGoogle Scholar
  83. Marques HO: Hemostasis disturbances in patients with malaria. Master Dissertation. 2004, Federal University of São Paulo, Hematology DepartmentGoogle Scholar
  84. Oliveira MS: Hematological characterization of children with vivax malaria diagnosed and treated in the Fundação de Medicina Tropical do Amazonas. Master Dissertation. 2004, University of the Amazonas State, Health Sciences SchoolGoogle Scholar
  85. Silva IBA: Vivax malaria: clinical and laboratorial manifestations related to TNF-alpha. PhD Thesis. 2004, Federal University of ParáGoogle Scholar
  86. Raposo CCBS: Vivax malaria in Maranhão: epidemiological and clinical aspects. Master Dissertation. 2006, University of Brasília, Tropical Medicine DeprtmentGoogle Scholar
  87. Pereira MSS: Study of malaria in pregnant and puerperal women in a public maternity in Manaus from 1999 to 2004. Master Dissertation. 2006, Federal University of Amazonas, Health Sciences SchoolGoogle Scholar
  88. Guerreiro NSV: Clinical and epidemiological study of Plasmodium vivax malaria in the State of Amapá. Master Dissertation. 2006, Federal University of ParáGoogle Scholar
  89. Lacerda MVG: Clinical manifestations and pathogenesis of malarial thrombocytopenia. PhD Thesis. 2007, University of Brasília, Tropical Medicine DepartmentGoogle Scholar
  90. Silva SBR: Evaluation of frequency and factors associated to thrombocytopenia caused by Plasmodium vivax. Master Dissertation. 2009, Federal University of Mato GrossoGoogle Scholar
  91. Fragoso SCP: Study of 17 cases of autopsies from patients with the diagnosis of vivax malaria in a reference center in the Brazilian Amazon. Master Dissertation. 2010, University of the Amazonas State, Health Sciences SchoolGoogle Scholar
  92. Lança EFC: Children under 14 years with malaria admitted to Intensive Care Units in the Brazilian Amazon: a case-control study with Plasmodium vivax patients. Master Dissertation. 2011, University of the Amazonas State, Health Sciences SchoolGoogle Scholar
  93. Karunaweera ND, Wijesekera SK, Wanasekera D, Mendis KN, Carter R: The paroxysm of Plasmodium vivax malaria. Trends Parasitol. 2003, 19: 188-193.PubMedGoogle Scholar
  94. Zimmerman PA, Mehlotra RK, Kasehagen LJ, Kazura JW: Why do we need to know more about mixed Plasmodium species infections in humans?. Trends Parasitol. 2004, 20: 440-447.PubMed CentralPubMedGoogle Scholar
  95. Quintero JP, Siqueira AM, Tobon A, Blair S, Moreno A, Arevalo-Herrera M, Lacerda MV, Valencia SH: Malaria-related anaemia: a Latin American perspective. Mem Inst Oswaldo Cruz. 2011, 106 (Suppl 1): 91-104.PubMedGoogle Scholar
  96. Caicedo O, Ramirez O, Mourao MP, Ziadec J, Perez P, Santos JB, Quinones F, Alecrim MG, Arevalo-Herrera M, Lacerda MV, Herrera S: Comparative hematologic analysis of uncomplicated malaria in uniquely different regions of unstable transmission in Brazil and Colombia. Am J Trop Med Hyg. 2009, 80: 146-151.PubMedGoogle Scholar
  97. Michon P, Cole-Tobian JL, Dabod E, Schoepflin S, Igu J, Susapu M, Tarongka N, Zimmerman PA, Reeder JC, Beeson JG, Schofield L, King CL, Mueller I: The risk of malarial infections and disease in Papua New Guinean children. Am J Trop Med Hyg. 2007, 76: 997-1008.PubMed CentralPubMedGoogle Scholar
  98. Rodriguez-Morales AJ, Sanchez E, Vargas M, Piccolo C, Colina R, Arria M: Anemia and thrombocytopenia in children with Plasmodium vivax malaria. J Trop Pediatr. 2006, 52: 49-51.PubMedGoogle Scholar
  99. Poespoprodjo JR, Fobia W, Kenangalem E, Lampah DA, Hasanuddin A, Warikar N, Sugiarto P, Tjitra E, Anstey NM, Price RN: Vivax malaria: a major cause of morbidity in early infancy. Clin Infect Dis. 2009Google Scholar
  100. Katsuragawa TH, Cunha RP, Souza DC, Gil LH, Cruz RB, Silva AA, Tada MS, Silva LHP: Malaria and hematological aspects among residents to be impacted by reservoirs for the Santo Antonio and Jirau Hydroelectric Power Stations, Rondonia State, Brazil. Cad Saude Publica. 2009, 25: 1486-1492.PubMedGoogle Scholar
  101. Ferreira MU, Silva-Nunes M, Bertolino CN, Malafronte RS, Muniz PT, Cardoso MA: Anemia and iron deficiency in school children, adolescents, and adults: a community-based study in rural Amazonia. Am J Public Health. 2007, 97: 237-239.PubMed CentralPubMedGoogle Scholar
  102. Cardoso MA, Ferreira MU, Camargo LM, Szarfarc SC: Anaemia, iron deficiency and malaria in a rural community in Brazilian Amazon. Eur J Clin Nutr. 1994, 48: 326-332.PubMedGoogle Scholar
  103. Wildig J, Michon P, Siba P, Mellombo M, Ura A, Mueller I, Cossart Y: Parvovirus B19 infection contributes to severe anemia in young children in Papua New Guinea. J Infect Dis. 2006, 194: 146-153.PubMedGoogle Scholar
  104. Kochar DK, Das A, Kochar A, Middha S, Acharya J, Tanwar GS, Gupta A, Pakalapati D, Garg S, Saxena V, Subudhi AK, Boopathi PA, Sirohi P, Kochar SK: Thrombocytopenia in Plasmodium falciparum, Plasmodium vivax and mixed infection malaria: A study from Bikaner (Northwestern India). Platelets. 2010, 21: 623-627.PubMedGoogle Scholar
  105. Lacerda MV, Mourao MP, Coelho HC, Santos JB: Thrombocytopenia in malaria: who cares?. Mem Inst Oswaldo Cruz. 2011, 106 (Suppl 1): 52-63.PubMedGoogle Scholar
  106. Guidelines for the treatment of malaria. [http://whqlibdoc.who.int/publications/2010/9789241547925_eng.pdf]
  107. Takaki K, Aoki T, Akeda H, Kajiwara T, Honda S, Maeda Y, Okada K, Sawae Y: A case of Plasmodium vivax malaria with findings of DIC (abstract). Kansenshogaku Zasshi. 1991, 65: 488-492.PubMedGoogle Scholar
  108. Lakhkar BB, Babu S, Shenoy V: DIC in vivax malaria. Indian Pediatr. 1996, 33: 971-972.PubMedGoogle Scholar
  109. Mourao MP, Lacerda MV, Macedo VO, Santos JB: Thrombocytopenia in patients with dengue virus infection in the Brazilian Amazon. Platelets. 2007, 18: 605-612.PubMedGoogle Scholar
  110. Santana VS, Lavezzo LC, Mondini A, Terzian AC, Bronzoni RV, Rossit AR, Machado RL, Rahal P, Nogueira MC, Nogueira ML: Concurrent Dengue and malaria in the Amazon region. Rev Soc Bras Med Trop. 2010, 43: 508-511.Google Scholar
  111. Charrel RN, Brouqui P, Foucault C, Lamballerie X: Concurrent dengue and malaria. Emerg Infect Dis. 2005, 11: 1153-1154.PubMed CentralPubMedGoogle Scholar
  112. WHO: Severe falciparum malaria. Trans R Soc Trop Med Hyg. 2000, 94 (Supp 1): S1-S90.Google Scholar
  113. Illamperuma C, Allen BL: Pulmonary edema due to Plasmodium vivax malaria in an American Missionary. Infection. 2007, 35: 374-376.PubMedGoogle Scholar
  114. Pukrittayakamee S, Chantra A, Vanijanonta S, White NJ: Pulmonary oedema in vivax malaria. Trans R Soc Trop Med Hyg. 1998, 92: 421-422.PubMedGoogle Scholar
  115. Tan LK, Yacoub S, Scott S, Bhagani S, Jacobs M: Acute lung injury and other serious complications of Plasmodium vivax malaria. Lancet Infect Dis. 2008, 8: 449-454.PubMedGoogle Scholar
  116. Anstey NM, Russell B, Yeo TW, Price RN: The pathophysiology of vivax malaria. Trends Parasitol. 2009, 25: 220-227.PubMedGoogle Scholar
  117. Menendez C, Romagosa C, Ismail MR, Carrilho C, Saute F, Osman N, Machungo F, Bardaji A, Quinto L, Mayor A, Naniche D, Dobano C, Alonso PL, Ordi J: An autopsy study of maternal mortality in Mozambique: the contribution of infectious diseases. PLoS Med. 2008, 5: e44PubMed CentralPubMedGoogle Scholar
  118. Kochar SK, Mahajan M, Gupta RP, Middha S, Acharya J, Kochar A, Das A, Kochar DK: Acute attack of AIP (acute intermittent porphyria) with severe vivax malaria associated with convulsions: a case report. J Vector Borne Dis. 2009, 46: 307-309.PubMedGoogle Scholar
  119. Lampah DA, Yeo TW, Hardianto SO, Tjitra E, Kenangalem E, Sugiarto P, Price RN, Anstey NM: Coma associated with microscopy-diagnosed plasmodium vivax: a prospective study in Papua, Indonesia. PLoS Negl Trop Dis. 2011, 5: e1032PubMed CentralPubMedGoogle Scholar
  120. Cavasini MT, Ribeiro WL, Kawamoto F, Ferreira MU: How prevalent is Plasmodium malariae in Rondonia, western Brazilian Amazon?. Rev Soc Bras Med Trop. 2000, 33: 489-492.PubMedGoogle Scholar
  121. Costa AP, Bressan CS, Pedro RS, Valls-de-Souza R, Silva S, Souza PR, Guaraldo L, Ferreira-da-Cruz MF, Daniel-Ribeiro CT, Brasil P: Delayed diagnosis of malaria in a dengue endemic area in the Brazilian extra-Amazon: recent experience of a malaria surveillance unit in state of Rio de Janeiro. Rev Soc Bras Med Trop. 2010, 43: 571-574.Google Scholar
  122. Kochar DK, Tanwar GS, Khatri PC, Kochar SK, Sengar GS, Gupta A, Kochar A, Middha S, Acharya J, Saxena V, Pakalapati D, Garg S, Das A: Clinical features of children hospitalized with malaria-a study from Bikaner, northwest India. Am J Trop Med Hyg. 2010, 83: 981-989.PubMed CentralPubMedGoogle Scholar
  123. Kochar DK, Das A, Kochar SK, Saxena V, Sirohi P, Garg S, Kochar A, Khatri MP, Gupta V: Severe Plasmodium vivax malaria: a report on serial cases from Bikaner in northwestern India. Am J Trop Med Hyg. 2009, 80: 194-198.PubMedGoogle Scholar
  124. Kochar DK, Singh P, Agarwal P, Kochar SK, Pokharna R, Sareen PK: Malarial hepatitis. J Assoc Physicians India. 2003, 51: 1069-1072.PubMedGoogle Scholar
  125. Khan FY, El-Hiday AH: Acute acalculous cholecystitis complicating an imported case of mixed malaria caused by Plasmodium falciparum and Plasmodium vivax. Int J Infect Dis. 2010, 14 (Suppl 3): e217-219.PubMedGoogle Scholar
  126. Kumar A, Katiyar GP: Mixed infection with Plasmodium vivax and Salmonella typhi in an infant. Indian Pediatr. 1995, 32: 243-244.PubMedGoogle Scholar
  127. Piyaphanee W, Issarachaikul R, Soontarach P, Silachamroon U: Concurrent salmonella bacteremia in P. vivax infection--a report of 2 cases at the Hospital for Tropical Diseases, Thailand. Southeast Asian J Trop Med Public Health. 2007, 38: 616-618.PubMedGoogle Scholar
  128. Fonseca JC: Natural history of chronic hepatitis B. Rev Soc Bras Med Trop. 2007, 40: 672-677.PubMedGoogle Scholar
  129. Lacerda MV, Mourao MP, Santos PJ, Alecrim MG: Algid malaria: a syndromic diagnosis. Rev Soc Bras Med Trop. 2009, 42: 79-81.PubMedGoogle Scholar
  130. Stoppacher R, Adams SP: Malaria deaths in the United States: case report and review of deaths, 1979-1998. J Forensic Sci. 2003, 48: 404-408.PubMedGoogle Scholar
  131. Bassat Q, Guinovart C, Sigauque B, Mandomando I, Aide P, Sacarlal J, Nhampossa T, Bardaji A, Morais L, Machevo S, Letang E, Macete E, Aponte JJ, Roca A, Menendez C, Alonso PL: Severe malaria and concomitant bacteraemia in children admitted to a rural Mozambican hospital. Trop Med Int Health. 2009, 14: 1011-1019.PubMedGoogle Scholar
  132. Song JY, Park CW, Jo YM, Kim JY, Kim JH, Yoon HJ, Kim CH, Lim CS, Cheong HJ, Kim WJ: Two cases of Plasmodium vivax malaria with the clinical picture resembling toxic shock. Am J Trop Med Hyg. 2007, 77: 609-611.PubMedGoogle Scholar
  133. Anstey NM, Handojo T, Pain MC, Kenangalem E, Tjitra E, Price RN, Maguire GP: Lung injury in vivax malaria: pathophysiological evidence for pulmonary vascular sequestration and posttreatment alveolar-capillary inflammation. J Infect Dis. 2007, 195: 589-596.PubMed CentralPubMedGoogle Scholar
  134. Carvalho BO, Lopes SC, Nogueira PA, Orlandi PP, Bargieri DY, Blanco YC, Mamoni R, Leite JA, Rodrigues MM, Soares IS, Oliveira TR, Wunderlich G, Lacerda MV, Del Portillo HA, Araujo MO, Russell B, Suwanarusk R, Snounou G, Renia L, Costa FT: On the Cytoadhesion of Plasmodium vivax-Infected Erythrocytes. J Infect Dis. 2010, 202: 638-647.PubMedGoogle Scholar
  135. Echeverri M, Tobon A, Alvarez G, Carmona J, Blair S: Clinical and laboratory findings of Plasmodium vivax malaria in Colombia, 2001. Rev Inst Med Trop São Paulo. 2003, 45: 29-34.PubMedGoogle Scholar
  136. Nosten F, McGready R, Simpson JA, Thwai KL, Balkan S, Cho T, Hkirijaroen L, Looareesuwan S, White NJ: Effects of Plasmodium vivax malaria in pregnancy. Lancet. 1999, 354: 546-549.PubMedGoogle Scholar
  137. Poespoprodjo JR, Fobia W, Kenangalem E, Lampah DA, Warikar N, Seal A, McGready R, Sugiarto P, Tjitra E, Anstey NM, Price RN: Adverse pregnancy outcomes in an area where multidrug-resistant Plasmodium vivax and Plasmodium falciparum infections are endemic. Clin Infect Dis. 2008, 46: 1374-1381.PubMed CentralPubMedGoogle Scholar
  138. Martinez-Espinosa FE, Daniel-Ribeiro CT, Alecrim WD: Malaria during pregnancy in a reference centre from the Brazilian Amazon: unexpected increase in the frequency of Plasmodium falciparum infections. Mem Inst Oswaldo Cruz. 2004, 99: 19-21.PubMedGoogle Scholar
  139. Poels PJ, Dolmans WM, Gabreels FJ: Rhabdomyolysis associated with malaria tertiana in a patient with myoadenylate deaminase deficiency. Trop Geogr Med. 1993, 45: 83-86.PubMedGoogle Scholar
  140. Hamel CT, Blum J, Harder F, Kocher T: Nonoperative treatment of splenic rupture in malaria tropica: review of literature and case report. Acta Trop. 2002, 82: 1-5.PubMedGoogle Scholar
  141. Lewallen S, Harding SP, Ajewole J, Schulenburg WE, Molyneux ME, Marsh K, Usen S, White NJ, Taylor TE: A review of the spectrum of clinical ocular fundus findings in P. falciparum malaria in African children with a proposed classification and grading system. Trans R Soc Trop Med Hyg. 1999, 93: 619-622.PubMedGoogle Scholar
  142. Lee JH, Chin HS, Chung MH, Moon YS: Retinal Hemorrhage in Plasmodium vivax Malaria. Am J Trop Med Hyg. 2010, 82: 219-222.PubMed CentralPubMedGoogle Scholar
  143. Vitor-Silva S, Reyes-Lecca RC, Pinheiro TR, Lacerda MV: Malaria is associated with poor school performance in an endemic area of the Brazilian Amazon. Malar J. 2009, 8: 230PubMed CentralPubMedGoogle Scholar
  144. Williams TN, Maitland K, Phelps L, Bennett S, Peto TE, Viji J, Timothy R, Clegg JB, Weatherall DJ, Bowden DK: Plasmodium vivax: a cause of malnutrition in young children. QJM. 1997, 90: 751-757.PubMedGoogle Scholar
  145. Pereira PC, Meira DA, Curi PR, Souza N, Burini RC: The malarial impact on the nutritional status of Amazonian adult subjects. Rev Inst Med Trop Sao Paulo. 1995, 37: 19-24.PubMedGoogle Scholar
  146. Ventura AM, Pinto AY, Silva RS, Calvosa VS, Silva Filho MG, Souza JM: Plasmodium vivax malaria in children and adolescents - epidemiological, clinical and laboratory features. J Pediatr (Rio J). 1999, 75: 187-194.Google Scholar
  147. Silamut K, White NJ: Relation of the stage of parasite development in the peripheral blood to prognosis in severe falciparum malaria. Trans R Soc Trop Med Hyg. 1993, 87: 436-443.PubMedGoogle Scholar
  148. Andrade BB, Reis-Filho A, Souza-Neto SM, Raffaele-Netto I, Camargo LM, Barral A, Barral-Netto M: Plasma superoxide dismutase-1 as a surrogate marker of vivax malaria severity. PLoS Negl Trop Dis. 2010, 4: e650PubMed CentralPubMedGoogle Scholar
  149. Santana MS, Lacerda MVG, Barbosa MGV, Alecrim WD, Alecrim MGC: Glucose-6-phosphate dehydrogenase deficiency in an endemic area for malaria in Manaus: a cross-sectional survey in the Brazilian Amazon. PLoS ONE. 2009, 4: e5259PubMed CentralPubMedGoogle Scholar
  150. Leslie T, Briceno M, Mayan I, Mohammed N, Klinkenberg E, Sibley CH, Whitty CJ, Rowland M: The impact of phenotypic and genotypic G6PD deficiency on risk of Plasmodium vivax infection: a case-control study amongst Afghan refugees in Pakistan. PLoS Med. 2010, 7: e1000283PubMed CentralPubMedGoogle Scholar
  151. Guindo A, Fairhurst RM, Doumbo OK, Wellems TE, Diallo DA: X-linked G6PD deficiency protects hemizygous males but not heterozygous females against severe malaria. PLoS Med. 2007, 4: e66PubMed CentralPubMedGoogle Scholar
  152. Cavasini CE, de Mattos LC, Couto AA, Couto VS, Gollino Y, Moretti LJ, Bonini-Domingos CR, Rossit AR, Castilho L, Machado RL: Duffy blood group gene polymorphisms among malaria vivax patients in four areas of the Brazilian Amazon region. Malar J. 2007, 6: 167PubMed CentralPubMedGoogle Scholar
  153. Cavasini CE, Mattos LC, Couto AA, Bonini-Domingos CR, Valencia SH, Neiras WC, Alves RT, Rossit AR, Castilho L, Machado RL: Plasmodium vivax infection among Duffy antigen-negative individuals from the Brazilian Amazon region: an exception?. Trans R Soc Trop Med Hyg. 2007, 101: 1042-1044.PubMedGoogle Scholar
  154. Albuquerque SR, Cavalcante F, de O, Sanguino EC, Tezza L, Chacon F, Castilho L, dos Santos MC: FY polymorphisms and vivax malaria in inhabitants of Amazonas State, Brazil. Parasitol Res. 2010, 106: 1049-1053.PubMedGoogle Scholar
  155. Costa FT, Lopes SC, Ferrer M, Leite JA, Martin-Jaular L, Bernabeu M, Nogueira PA, Mourao MP, Fernandez-Becerra C, Lacerda MV, Portillo HD: On cytoadhesion of Plasmodium vivax: raison d'etre?. Mem Inst Oswaldo Cruz. 2011, 106 (Suppl 1): 79-84.PubMedGoogle Scholar
  156. Campos FM, Franklin BS, Teixeira-Carvalho A, Filho AL, de Paula SC, Fontes CJ, Brito CF, Carvalho LH: Augmented plasma microparticles during acute Plasmodium vivax infection. Malar J. 2010, 9: 327PubMed CentralPubMedGoogle Scholar
  157. Andrade BB, Araujo-Santos T, Luz NF, Khouri R, Bozza MT, Camargo LM, Barral A, Borges VM, Barral-Netto M: Heme impairs prostaglandin E2 and TGF-beta production by human mononuclear cells via Cu/Zn superoxide dismutase: insight into the pathogenesis of severe malaria. J Immunol. 2010, 185: 1196-1204.PubMedGoogle Scholar
  158. Erel O, Vural H, Aksoy N, Aslan G, Ulukanligil M: Oxidative stress of platelets and thrombocytopenia in patients with vivax malaria. Clin Biochem. 2001, 34: 341-344.PubMedGoogle Scholar
  159. Araujo CF, Lacerda MV, Abdalla DS, Lima ES: The role of platelet and plasma markers of antioxidant status and oxidative stress in thrombocytopenia among patients with vivax malaria. Mem Inst Oswaldo Cruz. 2008, 103: 517-521.PubMedGoogle Scholar
  160. Grynberg P, Fernandes Fontes CJ, Martins Braga E: Association between particular polymorphic residues on apical membrane antigen 1 (AMA-1) and platelet levels in patients with vivax malaria. Clin Microbiol Infect. 2007Google Scholar
  161. Fernandes AA, Carvalho LJ, Zanini GM, Ventura AM, Souza JM, Cotias PM, Silva-Filho IL, Daniel-Ribeiro CT: Similar cytokine responses and degrees of anemia in patients with Plasmodium falciparum and Plasmodium vivax infections in the Brazilian Amazon region. Clin Vaccine Immunol. 2008, 15: 650-658.PubMed CentralPubMedGoogle Scholar
  162. Wickramasinghe SN, Abdalla SH: Blood and bone marrow changes in malaria. Baillieres Best Pract Res Clin Haematol. 2000, 13: 277-299.PubMedGoogle Scholar
  163. Fernandez-Becerra C, Yamamoto MM, Vencio RZ, Lacerda M, Rosanas-Urgell A, Del Portillo HA: Plasmodium vivax and the importance of the subtelomeric multigene vir superfamily. Trends Parasitol. 2008, 25: 44-51.PubMedGoogle Scholar
  164. Santos-Ciminera PD, Alecrim MD, Roberts DR, Quinnan GV: Molecular epidemiology of Plasmodium vivax in the State of Amazonas, Brazil. Acta Trop. 2007Google Scholar
  165. Bussaratid V, Walsh DS, Wilairatana P, Krudsood S, Silachamroon U, Looareesuwan S: Frequency of pruritus in Plasmodium vivax malaria patients treated with chloroquine in Thailand. Trop Doct. 2000, 30: 211-214.PubMedGoogle Scholar
  166. Sahoo S, Kumar M, Sinha VK: Chloroquine-induced recurrent psychosis. Am J Ther. 2007, 14: 406-407.PubMedGoogle Scholar
  167. Katsuragawa TH, Gil LHS, Stabile RG, Pires MG, Bonini-Domingos CR: Incidence evaluation of Glucose-6-Phosphate Dehydrogenase and hematological profile in Rondônia. Rev Bras Hematol Hemoter. 2004, 26: 268-273.Google Scholar
  168. Silva MC, Santos EB, Costal EG, Filho MG, Guerreiro JF, Povoa MM: Clinical and laboratorial alterations in Plasmodium vivax malaria patients and glucose-6-phosphate dehydrogenase deficiency treated with primaquine at 0.50 mg/kg/day. Rev Soc Bras Med Trop. 2004, 37: 215-217.PubMedGoogle Scholar
  169. Walsh DS, Wilairatana P, Tang DB, Heppner DG, Brewer TG, Krudsood S, Silachamroon U, Phumratanaprapin W, Siriyanonda D, Looareesuwan S: Randomized trial of 3-dose regimens of tafenoquine (WR238605) versus low-dose primaquine for preventing Plasmodium vivax malaria relapse. Clin Infect Dis. 2004, 39: 1095-1103.PubMedGoogle Scholar
  170. Price RN, Douglas NM, Anstey NM: New developments in Plasmodium vivax malaria: severe disease and the rise of chloroquine resistance. Curr Opin Infect Dis. 2009, 22: 430-435.PubMedGoogle Scholar
  171. Alecrim MG, Alecrim W, Macedo V: Plasmodium vivax resistance to chloroquine (R2) and mefloquine (R3) in Brazilian Amazon region. Rev Soc Bras Med Trop. 1999, 32: 67-68.PubMedGoogle Scholar
  172. Santana Filho FS, Arcanjo AR, Chehuan YM, Costa MR, Martinez-Espinosa FE, Vieira JL, Barbosa MG, Alecrim WD, Alecrim MG: Chloroquine-resistant Plasmodium vivax, Brazilian Amazon. Emerg Infect Dis. 2007, 13: 1125-1126.PubMed CentralPubMedGoogle Scholar
  173. Orjuela-Sanchez P, Santana Filho FS, Machado-Lima A, Chehuan YF, Costa MR, Alecrim MD, Del Portillo HA: Analysis of single-nucleotide polymorphisms in the crt-o and mdr1 genes of Plasmodium vivax among chloroquine resistant isolates from the Brazilian Amazon region. Antimicrob Agents Chemother. 2009Google Scholar
  174. Fernandez-Becerra C, Pinazo MJ, Gonzalez A, Alonso PL, Del Portillo HA, Gascon J: Increased expression levels of the pvcrt-o and pvmdr1 genes in a patient with severe Plasmodium vivax malaria. Malar J. 2009, 8: 55PubMed CentralPubMedGoogle Scholar
  175. Douglas NM, Anstey NM, Angus BJ, Nosten F, Price RN: Artemisinin combination therapy for vivax malaria. Lancet Infect Dis. 2010, 10: 405-416.PubMed CentralPubMedGoogle Scholar
  176. Pessoa SB: Parasitologia Médica. 1967, Rio de Janeiro: Guanabara-Koogan, 11Google Scholar
  177. Alves FP, Durlacher RR, Menezes MJ, Krieger H, Silva LH, Camargo EP: High prevalence of asymptomatic Plasmodium vivax and Plasmodium falciparum infections in native Amazonian populations. Am J Trop Med Hyg. 2002, 66: 641-648.PubMedGoogle Scholar
  178. Halstead SB: Dengue. Curr Opin Infect Dis. 2002, 15: 471-476.PubMedGoogle Scholar

Copyright

© Lacerda et al; licensee BioMed Central Ltd. 2011

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement